Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017
| Title: | Comparative Study of AEFI of Hepatitis B Vaccine between Iran Ministry of Health CDC and VAERS Data during 2015 to 2017 |
|---|---|
| Authors: | Hamidreza Hozouri, Alireza Shamsian, Mohammadreza Aghasadeghi, Delaram Doroud |
| Source: | Vaccine Research, Vol 8, Iss 1, Pp 52-59 (2021) |
| Publisher Information: | Pasteur Institute of Iran, 2021. |
| Publication Year: | 2021 |
| Collection: | LCC:Medicine LCC:Science |
| Subject Terms: | aefi, rhbv, vaers, cdc, pasteur institute of iran, Medicine, Science |
| More Details: | Introduction: Hepatitis B Vaccine (HBV) is a safe and effective vaccine that is nowadays recommended for all infants at birth as well as adults who could be exposed to hepatitis B virus. HBV can provide lifetime protection against hepatitis B virus infection. Despite its highly effective disease prevention, HBV can also cause adverse effects for the vaccinated population. A vast majority of Iran's population are vaccinated with recombinant hepatitis B vaccine (rHBV) which is manufactured by the Production and Research Complex of Pasteur Institute of Iran. Methods: The reported adverse events of rHBV, obtained from Diseases Management Center of Iran’s Ministry of Health were compared with those in The Vaccine Adverse Event Reporting System (VAERS, a United States program for vaccine safety, co-managed by the U.S. Centers for Disease Control and Prevention) during 2015 to 2017. Results: The most common adverse events after administration of rHBV, manufactured by Pasteur Institute of Iran was injection site reactions and no life threatening adverse event was observed. Conclusion: Despite reports by VAERS indicating that HBV can cause adverse events and even death in the United States, no such adverse effects were observed in rHBV manufactured in Iran. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 2383-2819 2423-4923 |
| Relation: | http://vacres.pasteur.ac.ir/article-1-275-en.html; https://doaj.org/toc/2383-2819; https://doaj.org/toc/2423-4923 |
| DOI: | 10.52547/vacres.8.1.52 |
| Access URL: | https://doaj.org/article/aec3c63e7d6b422e9050eeb100b917ed |
| Accession Number: | edsdoj.3c63e7d6b422e9050eeb100b917ed |
| Database: | Directory of Open Access Journals |
| ISSN: | 23832819 24234923 |
|---|---|
| DOI: | 10.52547/vacres.8.1.52 |
| Published in: | Vaccine Research |
| Language: | English |